+

WO1998011880A1 - Comprimes de nettoyage d'appareils dentaires - Google Patents

Comprimes de nettoyage d'appareils dentaires Download PDF

Info

Publication number
WO1998011880A1
WO1998011880A1 PCT/US1997/016026 US9716026W WO9811880A1 WO 1998011880 A1 WO1998011880 A1 WO 1998011880A1 US 9716026 W US9716026 W US 9716026W WO 9811880 A1 WO9811880 A1 WO 9811880A1
Authority
WO
WIPO (PCT)
Prior art keywords
acid
alkali metal
phase
tablet according
base material
Prior art date
Application number
PCT/US1997/016026
Other languages
English (en)
Inventor
Simon Andrew Martin Gardiner
Iain Allan Hughes
Original Assignee
The Procter & Gamble Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Procter & Gamble Company filed Critical The Procter & Gamble Company
Publication of WO1998011880A1 publication Critical patent/WO1998011880A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/42—Amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0216—Solid or semisolid forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/22—Peroxides; Oxygen; Ozone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37—Esters of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • A61Q11/02—Preparations for deodorising, bleaching or disinfecting dentures

Definitions

  • the present invention relates to cleansing compositions in tablet form, and especially to compositions for use in cleansing dentures and the like.
  • the invention relates to tablet-form compositions having more rapid and useful denture cleansing performance and anti-bacterial activity.
  • Effervescent tablets for cleansing dentures and the like are well known in the art.
  • the aim of a denture cleanser product is to clean the denture as fully and as quickly as possible and especially to remove the accummulation of plaque, mucilageneous and bacterial deposits which collect while the denture is being worn.
  • To wear a denture which has not been completely cleaned of plaque and bacterial deposits is not only unhygienic but can also within a short space of time result in a detrimental effect on the mucous membrane.
  • bacterial deposits can lead to so-called bacterial corrosion of the plastics material used to produce the denture with consequent color- change and malodor-formation.
  • the present invention provides a denture cleanser which cleanses more rapidly and which is more felicitous on plaque, mucilageneous and bacterial deposits than those preparations which are presently known and available on the market.
  • EP-A-0253772 discloses denture cleansers comprising bleach activator granules including a polymeric fl ⁇ orocarbon binder.
  • EP-A-0323049 discloses denture cleanser tablets comprising an inorganic persalt bleaching agent, an organic peroxyacid bleach precursor and a solid base material which comprises at least one alkali metal carbonate or bicarbonate and at least one organic acid and which in the presence of water releases carbon dioxide with effervescence.
  • a cleansing tablet for dentures comprising an inorganic persalt bleaching agent, an organic peroxyacid bleach precursor and a solid base material which comprises at least one non-toxic, physiologically-acceptable inorganic acid and at least one alkali metal carbonate or bicarbonate and which in the presence of water releases carbon dioxide with effervescence and wherein are excluded denture cleansing tablets wherein the solid base material additionally comprises an organic acid.
  • the cleansing tablets of the invention thus comprise three essential components, a bleaching agent, a peroxyacid bleach precursor and an effervescence producing base composition. Each of these will be discussed in turn.
  • the bleaching agent takes the form of the inorganic persalt and can be selected from any of the well-known bleaching agents l nown for use in denture cleansers such as the alkali metal and ammonium persulfates, perborates and perphosphates and the alkali metal and alkaline earth metal peroxides.
  • suitable bleaching agents include potassium, ammonium, sodium and lithium persulfates and perborate mono- and tetrahydrates, sodium pyrophosphate peroxyhydrate and magnesium, calcium, strontium and zinc peroxides.
  • the alkali metal persulfates, perborates and mixtures thereof are highly preferred for use herein.
  • the amount of bleaching agent in the total composition is generally from about 5 to about 70% preferably from about 10% to about 50%.
  • the overall persulfate: perborate ratio is preferably from about 5: 1 to about 1 :5, more preferably from about 2: 1 to about 1 :2.
  • the compositions herein also contain an organic peroxyacid precursor, which in general terms can be defined as a compound having a titre of at least 1.5 ml of 0.1N sodium thiosulfate in the following peracid formulation test.
  • test solution is prepared by dissolving the following materials in 1000 mis distilled water:
  • sodium pyrophosphate Na P2 ⁇ . IOH2O
  • sodium perborate NaBO2-H2 O2.3H2 O
  • sodium dodecylbenzene sulphonate 0.5 g
  • the organic peracid precursors are typically compounds containing one or more acyl groups, which are susceptible to perhydrolysis.
  • the preferred activators are those of the N-acyl or O-acyl compound type containing an acyl radical R--CO wherein R is a hydrocarbon or substituted hydrocarbon group having preferably from about 1 to about 20 carbon atoms.
  • suitable peracid precursors include.
  • Examples of compounds of this type include phenyl acetate, sodium acetoxy benzene sulphonate, trichloroethylacetate, sorbitol hexaacetate, fructose pentaacetate, p-nitrobenzaldehyde diacetate, isopropeneyl acetate, acetyl aceto hydroxamic acid, and acetyl salicylic acid.
  • esters of a phenol or substituted phenol with an alpha-chlorinated lower aliphatic carboxylic acid such as chloroacetylphenol and chloroacetylsalicylic acid, as disclosed in U.S. Pat. No. 3,130,165.
  • Preferred compounds of this type are those wherein: a) Ac is R3 —CO and R3 is a linear or branched alkyl group containing from 6 to 20, preferably 6 to 12, more preferably 7 to 9 carbon atoms and wherein the longest linear alkyl chain extending from and including the carbonyl carbon contains from 5 to 18, preferably 5 to 10 carbon atoms, R3 optionally being substituted (preferably alpha to the carbonyl moiety) by Cl, Br, OCH3 or OC2 H5.
  • this class of material examples include sodium 3,5,5,-trimethylhexanoyloxybenzene sulfonate, sodium 3,5,5- trimethylhexanoyloxybenzoate, sodium 2-ethylhexanoyl oxybenzenesulfonate, sodium nonanoyl oxybenzene sulfonate and sodium octanoyl oxybenzenesulfonate, the acyloxy group in each instance preferably being p-subsituted; b) Ac has the formula R3 (AO) m XA wherein R3 is a linear or branched alkyl or alkylaryl group containing from 6 to 20, preferably from 6 to 15 carbon atoms in the alkyl moiety, R3 being optionally subsituted by Cl, Br, OCH3 or OC2 H5, AO is oxyethylene or oxypropylene, m is from 0 to 100, X is O NR or CO--NR4, and A is CO
  • Bleach activator compounds of this type include carbonic acid derivatives of the formula R3 (AO).sub.m OCOL, succinic acid derivatives of the formula R3 OCO(CH2)2 COL, glycollic acid derivatives of the formula R3 OCH2 COL, hydroxypropionic acid derivatives of the formula R3 OCH2 CH2 COL, oxalic acid derivatives of the formula R3 OCOCOL, maleic and fumaric acid derivatives of the formula R3 OCOCH.dbd.CHCOL, acyl aminocaproic acid derivatives of the formula R3 CONR] (CH2>6 COL, acyl qlycine derivatives of the formula R3 CONRj CH2 COL, and amino-6-oxocaproic acid derivatives of the formula R3 N(Rj)CO(CH2)4 COL.
  • m is preferably from 0 to 10
  • R3 is preferably Cg -C12, more preferably C -C ⁇ Q alkyl when m is zero and C9 -C 15 when m is non-zero.
  • the leaving group L is as defined above.
  • Optionally substituted anhydrides of benzoic or phthalic acid for example benzoic anhydride, m-chlorobenzoic anydride and phthalic anhydride.
  • organic peracid precursors of types 1(c) and 4(a) are particularly preferred. Particularly preferred for use herein are organic peracid precursors of type 1(c), especially N.KN ⁇ N-tetraacetylethylenediamine (T-AED)
  • the level of peroxyacid bleach precursor by weight of the total composition is preferably from about 0.1% to about 10%, more preferably from about 0.5% to about 5%.
  • the effervescent solid base material of the compositions herein comprises a combination of at least one alkali metal carbonate or bi-carbonate, such as sodium bicarbonate, sodium carbonate, sodium sesquicarbonate, potassium carbonate, potassium bicarbonate, or mixtures thereof, in admixture with at least one non-toxic, physiologically-acceptable inorganic acid, such as sulphamic acid, sodium or potassium acid phosphates, phosphoric acid, pyrophosphoric acid and sodium borohydride or mixtures thereof.
  • a particularly preferred inorganic acid for use herein is sulphamic acid.
  • the (bi)carbonate components generally comprise from about 5% to about 65%, preferably from about 25% to 55% of the total tablet; the acid components generally comprise from about 5% to about 50%, preferably from about 10% to about 40% of the total tablet.
  • the solid base material in the compositions herein must not contain an organic acid.
  • the solid base material comprises two or more component phases having differing pH in aqueous medium, at least one of the component phases having an acidic pH.
  • the inorganic bleaching agent preferably comprises an alkali metal persulfate and the acidic phase incorporates therein the organic peroxyacid bleach precursor and at least a portion, preferably from about 10% to about 40%, more preferably from about 15% to about 30% of the alkali metal persulfate.
  • the solid base material also comprises at least one phase having an alkaline pH.
  • the inorganic bleaching agent preferably comprises both an alkali metal persulfate and an alkali metal perborate, the acidic phase incorporating therein the organic peroxyacid bleach precursor and at least a portion, preferably from about 10% to about 40%, more preferably from about 15% to about 30% of the alkali metal persulfate, and the alkaline phase incorporating therein the alkali metal perborate.
  • the cleansing tablet is preferably designed in such a way that the alkaline phase dissolves or disperses in water more slowly or later than the acidic phase in order to provide, on placing the tablet in water, an initial pH in the acidic range, preferably from about 2 to about 6.5 and especially from about 3 to about 5.
  • the alkaline phase be present in sufficient excess of the acidic phase in order to shift, upon completion of effervescence, the pH of the aqueous medium into the alkaline range, preferably to a pH of from about 7.5 to about 9.
  • the initial acidic pH should be maintained for a time from about 30 seconds to about 3 hours, preferably from about 1 minute to about 60 minutes and especially from about 12 to about 30 minutes.
  • the slower dissolution rate of the alkaline phase compared with the acidic phase can be achieved in various ways, for example by the use of alkaline salts or compounds which are inherently sparingly or slowly soluble such as anhydrous sodium carbonate, calcium carbonate, calcium hydroxide, magnesium oxide, or magnesium hydroxide carbonate; or by converting at least a portion of the alkaline phase into a state of slower dissolution rate, for example by melting some of the alkaline phase components to form melt agglomerates followed by comminution to the desired particle size, or by compressing the alkaline phase components with a iller which has a slow dissolution rate such as anhydrous sodium sulfate and slowly water-soluble polymers, for example, proteins, cellulose ethers, cellulose esters, polyvinyl alcohol, alginic acid esters, vegetable fatty acid glycerides and other polymers having a colloidal or pseudo-colloidal character.
  • alkaline salts or compounds which are inherently sparingly or slowly soluble such
  • the relative rate of dissolution of the alkaline and acidic phases can be additionally controlled by appropriate formulation and distribution of the effervescent components of the solid base material.
  • the acidic phase at least, should incorporate both components of the carbonate or bicarbonate/acid effervescent couple and the effervescence factor of the acidic phase (i.e. the percentage of the phase represented by the least significant of the (bi)carbonate or acid components, measured on a stoichiometric basis) should be greater than that of the alkaline phase and preferably should be greater by a factor of at least 2, and more preferably at least 5.
  • the level of (bi)carbonate and acid components in the acid phase both generally lie in the range from about 10% to about 50% by weight thereof, and preferably from about 20% to about 40% thereof.
  • the alkaline phase contains a proportion of carbonate or bicarbonate (generally from about 5% to about 40%, preferably from about 10 % to about 30% thereof) but is substantially free of any acidic component so that the effervescence factor of the alkaline phase as defined herein is zero.
  • compositions of the invention can be in the form of monolayer tablets or can comprise two or more discrete layers.
  • monolayer tablet the alkaline and acidic phases are compressed, together with other optional constituents, to a tablet form using, for example, 1-5% by weight; referred to the total tablet composition, of polyvinylpyrrolidone, poly(oxyethylene) of molecular weight 20,000 to 500,000, polyethyleneglycols of molecular weight of from about 1000 to about 50,000 or Carbowax having a molecular weight of from 4000 to 20,000 as binder.
  • the multilayer tablets preferably at least one layer comprises the acidic phase and at least one other layer comprises the alkaline phase.
  • the overall ratio of acidic to alkaline phase in the compositions of the invention, both monolayer and multilayer, is preferably from about 10: 1 to about 1:20, more preferably from about 2.1 to about 1 :5 and especially from about 1: 1 to about 1 :3.
  • the multilayer tablets can- be prepared by precompressing the pregranulated components of a first layer of the multilayer tablet to a pressure of about 10 ⁇ kPa in a punch and dye tabletting press, adding the pregranulated components of the neighbouring layer with precompression as appropriate and repeating until the components of all layers of the tablet are in the press. The tablet is then given a final compression at about 1.5.10 kPa.
  • a binder as described above will normally be present in each of the layers of the multilayer tablet.
  • the solid base material of the compositions of the invention can be supplemented by other usual components of cleansing tablet formulations, especially surfactants, chelating agents, enzymes, flavor oils such as oils of spearmint, peppermint and wintergreen, dyestuffs, sweeteners, foam depressants such as dimethylpolysiloxanes, foam stabilizers such as the fatty acid sugar esters, preservatives, lubricants such as talc, magnesium stearate, finely divided amorphous pyrogenic silicas, etc.
  • the free moisture content of the final composition is desirably less than about 1% and especially less than about 0.5%.
  • the surface active agent used in the compositions of the invention can be selected from the many available that are compatible with the other ingredients of the denture cleanser, both in the dry state and in solution. Such materials are believed to improve the effectiveness of the other ingredients of the composition by aiding their penetration into the interdental surfaces. .Also, these materials aid in the removal of food debris attached to the teeth.
  • a dry powder or granular anionic surface active agent such as sodium lauryl sulfate, sodium N-lauroylsarcosinate, sodium lauryl sulfoacetate or dioctyl sodium sulfosuccinate or ricinoleyl sodium sulfosuccinate, may, for example, be included in the composition and preferably the surface active agent comprises between 2 and 4 percent of the composition.
  • Suitable cationic, non-ionic and ampholytic surface active agents include, for example, quaternary ammonium compounds such as cetyltrimethylammonium bromide, condensation products of al-kylene oxides such as ethylene or propylene oxide with fatty alcohols, phenols, fatty amines or fatty acid alkanolamides, the fatty acid alkanol amides themselves, esters of long-chained (Cg -C22) fatty acids with polyalcohols or sugars, for example glycerylmonostearate or saccharosemonolaurate or sorbitolpolyoxyethylenemono-or di-stearate, betaines, sulphobetaines or long- chain alkylaminocarboxylic acids.
  • quaternary ammonium compounds such as cetyltrimethylammonium bromide
  • condensation products of al-kylene oxides such as ethylene or propylene oxide with fatty alcohols, phenols, fatty amines
  • Chelating agents beneficially aid cleaning and bleach stability by keeping metal ions, such as calcium, magnesium, and heavy metal cations in solution.
  • suitable chelating agents include sodium tripolyphosphate, sodium acid pyrophosphate, tetrasodium pyrophosphate, aminopolycarboxylates such as nitrilotriacetic acid and ethylenediamine tetracetic acid and salts thereof, and polyphosphonates and aminopolyphosphonates such as hydroxyethanediphosphonic acid, ethylenediamine tetramethylenephosphonic acid, diethylenetriaminepentamethylenephosphonic acid and salts thereof.
  • the chelating agent selected is not critical except that it must be compatible with the other ingredients of the denture cleanser when in the dry state and in aqueous solution.
  • the chelating agent comprises between 0.1 and 60 percent by weight of the composition and preferably between 0.5 and 30 percent.
  • Phosphonic acid chelating agents preferably comprise from about 0.1 to about 1 percent, preferably from about 0.1% to about 0.5% by weight of composition.
  • Enzymes suitable for use herein are exemplified by proteases, alkalases, amylases, lipases, dextranases, mutanases, glucanases etc. The enzyme is expediently present in a discrete layer of a multilayer tablet.
  • the following are representative two-layer denture cleansing tablets according to the invention.
  • the percentages are by weight of the corresponding layer.
  • the weight ratio of alkaline layer: acidic layer in each instance is 70:30.
  • the overall tablet weight is 4 g; diameter 25 mm.
  • the denture cleansing tablets of Examples I to IV display more rapid and efficacious denture cleansing performance and bacterial activity than corresponding compositions which are free of peroxyacid bleach precursor.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Cosmetics (AREA)
  • Detergent Compositions (AREA)

Abstract

L'invention concerne des comprimés de nettoyage d'appareils dentaires contenant un agent de blanchiment au persel inorganique, un précurseur de blanchiment au peroxyacide organique, et une matière de base solide contenant au moins un carbonate ou un bicarbonate de métal alcalin, ainsi qu'au moins un acide inorganique non toxique physiologiquement acceptable, et qui, au contact de l'eau, dégage par effervescence du dioxyde de carbone. En sont exclus les comprimés de nettoyage d'appareils dentaires dans lesquels la matière de base solide est additionnée d'un acide organique. Cette composition permet un nettoyage d'appareils dentaires et une activité antibactérienne plus rapides et plus efficaces.
PCT/US1997/016026 1996-09-20 1997-09-10 Comprimes de nettoyage d'appareils dentaires WO1998011880A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9619644.9A GB9619644D0 (en) 1996-09-20 1996-09-20 Denture cleansing tablets
GB9619644.9 1996-09-20

Publications (1)

Publication Number Publication Date
WO1998011880A1 true WO1998011880A1 (fr) 1998-03-26

Family

ID=10800227

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/016026 WO1998011880A1 (fr) 1996-09-20 1997-09-10 Comprimes de nettoyage d'appareils dentaires

Country Status (2)

Country Link
GB (1) GB9619644D0 (fr)
WO (1) WO1998011880A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024204221A1 (fr) * 2023-03-27 2024-10-03 株式会社大阪製薬 Préparation de nettoyage solide

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5055305A (en) * 1988-12-02 1991-10-08 Richardson-Vicks, Inc. Cleansing compositions

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5055305A (en) * 1988-12-02 1991-10-08 Richardson-Vicks, Inc. Cleansing compositions

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024204221A1 (fr) * 2023-03-27 2024-10-03 株式会社大阪製薬 Préparation de nettoyage solide

Also Published As

Publication number Publication date
GB9619644D0 (en) 1996-11-06

Similar Documents

Publication Publication Date Title
US5055305A (en) Cleansing compositions
US5759523A (en) Detergent compositions comprising a dimethicone copolyol
AU629191B2 (en) Cleansing compositions
US6008171A (en) Cleansing compositions
KR100225666B1 (ko) 실리콘 조성물
EP0400858B1 (fr) Composition de nettoyage
AU700174B2 (en) Detergent composition comprising a dimethicone copolyol
CA2162667C (fr) Comprime de nettoyage de prothese dentaire contenant des particules grenues et agglomerees de precurseur de blanchiment
AU709629B2 (en) Cleansing compositions
WO1998011880A1 (fr) Comprimes de nettoyage d'appareils dentaires
CA2270422A1 (fr) Compositions de blanchiment effervescentes
KR100209998B1 (ko) 디메티콘 코폴리올을 함유하는 세정제 조성물
MXPA97004723A (en) Compositions cleaned
MXPA97004665A (en) Detergent composition comprising a dimetic copoliolde
JPH11500471A (ja) ジメチコーンコポリオールを含む洗浄組成物

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA CN TR US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: CA

122 Ep: pct application non-entry in european phase
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载